Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands by Jin, SC et al.
Contribution of rare transmitted and de novo variants among 2,871 1 
congenital heart disease probands 2 
 3 
Sheng Chih Jin1*, Jason Homsy2.3*, Samir Zaidi1*, Qiongshi Lu4, Sarah Morton5, 4 
Steven R. DePalma2, Xue Zeng1, Hongjian Qi6, Weni Chang7, Wei-Chien Hung1, 5 
Michael C. Sierant1, Shozeb Haider8, Junhui Zhang1, James Knight9, Robert D. 6 
Bjornson9, Christopher Castaldi9, Irina R. Tikhonoa9, Kaya Bilguvar9, Shrikant M. 7 
Mane9, Stephan J. Sanders10, Seema Mital11, Mark Russell12, William Gaynor13, 8 
John Deanfield14, Alessandro Giardini14, George A. Porter Jr.15, Deepak 9 
Srivastava16,17,18, Cecelia W. Lo19, Yufeng Shen20, W. Scott Watkins21, Mark 10 
Yandell21,22, H. Joseph Yost21, Martin Tristani-Firouzi23, Jane W. Newburger24, Amy 11 
E. Roberts24, Richard Kim25, Hongyu Zhao4, Jonathan R. Kaltman26, Elizabeth 12 
Goldmuntz27, Wendy K. Chung28, Jonathan G. Seidman2‡, Bruce D. Gelb29‡, 13 
Christine E. Seidman2,3,30†‡, Richard P. Lifton1,31†‡, Martina Brueckner1,32†‡ 14 
 15 
 16 
1Department of Genetics; Yale University School of Medicine, New Haven, CT, USA 17 
2Department of Genetics, Harvard Medical School, Boston, MA, USA 18 
3Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA 19 
4Department of Biostatistics; Yale School of Public Health, New Haven, CT, USA 20 
5Division of Newborn Medicine, Department of Medicine, Boston Children’s Hospital, 21 
Boston, USA 22 
6Department of Applied Physics and Applied Mathematics, Columbia University, New 23 
York, NY, USA 24 
7Department of Pediatrics, Columbia University Medical Center, New York, NY, USA 25 
8Department of Computational Chemistry, University College London School of 26 
Pharmacy, WC1N1AX, UK 27 
9Yale Center for Genome Analysis, Yale University, New Haven, CT, USA 28 
10Department of Psychiatry, University of California San Francisco, San Francisco, CA, 29 
USA 30 
11Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 31 
Toronto, Ontario, Canada 32 
12Division of Pediatric Cardiology, University of Michigan, Ann Arbor, MI, USA. 33 
13Department of Pediatric Cardiac Surgery, The Children's Hospital of Philadelphia, 34 
Philadelphia, PA, USA 35 
14Department of Cardiology, University College London and Great Ormond Street 36 
Hospital, London, UK 37 
15Department of Pediatrics, University of Rochester Medical Center, The School of 38 
Medicine and Dentistry, Rochester, NY, USA 39 
16Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA 40 
17Roddenberry Stem Cell Center at Gladstone, San Francisco, CA 94158, USA 41 
18Departments of Pediatrics and Biochemistry & Biophysics, University of California, San 42 
Francisco, San Francisco, CA 94158, USA 43 
19Department of Developmental Biology, University of Pittsburgh School of Medicine, 44 
Pittsburgh, Pennsylvania 15201, USA 45 
20Departments of Systems Biology and Biomedical Informatics, Columbia University 46 
Medical Center, New York, NY, USA 47 
21Department of Human Genetics, Eccles Institute of Human Genetics, University of 48 
Utah and School of Medicine, Salt Lake City, UT, USA 49 
22USTAR Center for Genetic Discovery, University of Utah, Salt Lake City, UT, USA 50 
23Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA 51 
24Department of Cardiology, Boston Children’s Hospital, Boston, MA, USA 52 
25Pediatric Cardiac Surgery, Children’s Hospital of Los Angeles, Los Angeles, CA, USA 53 
26Heart Development and Structural Diseases Branch, Division of Cardiovascular 54 
Sciences, NHLBI/NIH, Bethesda, MD, USA 55 
27Department of Pediatrics, The Perelman School of Medicine, University of 56 
Pennsylvania, Philadelphia, PA, USA 57 
28Departments of Pediatrics and Medicine, Columbia University Medical Center, New 58 
York, NY, USA 59 
29Mindich Child Health and Development Institute and Department of Pediatrics, Icahn 60 
School of Medicine at Mount Sinai, New York, NY, USA 61 
30Howard Hughes Medical Institute, Harvard University, Boston, MA, USA 62 
31Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, 63 
NY, USA 64 
32Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA 65 
*These authors contributed equally to this work. †These authors contributed equally to 66 
this work. ‡Corresponding author. E-mail: seidman@genetics.med.harvard.edu (J.G.S.);  67 
bruce.gelb@mssm.edu (B.D.G); cseidman@genetics.med.harvard.edu (C.E.S.); 68 
richard.lifton@rockefeller.edu (R.P.L); martina.brueckner@yale.edu (M.B.). 69 
70 
ABSTRACT 71 
Congenital heart disease (CHD) is the leading cause of mortality from birth defects. 72 
Exome sequencing of a single cohort of 2,871 CHD probands including 2,645 parent-73 
offspring trios implicated rare transmitted mutations in 1.8%, including a recessive 74 
founder mutation in GDF1 accounting for ~5% of severe CHD in Ashkenazim, recessive 75 
genotypes in MYH6 accounting for ~11% of Shone complex, and dominant FLT4 76 
mutations accounting for 2.3% of Tetralogy of Fallot. De novo mutations (DNMs) 77 
accounted for 8% of cases, including ~3% of isolated CHD patients and ~28% with both 78 
neurodevelopmental and extra-cardiac congenital anomalies. Seven genes surpassed 79 
thresholds for genome-wide significance and 19 genes not previously implicated in CHD 80 
had > 70% probability of being disease-related; DNMs in ~440 genes are inferred to 81 
contribute to CHD. There was striking overlap between genes with damaging DNMs in 82 
probands with CHD and autism. 83 
  84 
INTRODUCTION 85 
 86 
Congenital heart disease (CHD) affects approximately 1% of all live births and 87 
remains the leading cause of mortality from birth defects world-wide1. Despite dramatic 88 
improvement in surgical and medical care, these patients remain at risk for developing 89 
cardiac arrhythmias and heart failure. In addition, CHD patients are enriched for extra-90 
cardiac congenital anomalies (EA), and neurodevelopmental deficits2,3. While 91 
aneuploidies and copy number variations (CNVs) collectively account for ~23% of 92 
patients with CHD4-6, few individual causal genes have been implicated from these CNVs, 93 
thwarting a detailed understanding of disease mechanisms. Rare Mendelian, syndromic 94 
forms of CHD have allowed the identification of some CHD genes. Nonetheless, the 95 
genes underlying the large majority of sporadic cases of CHD have not been well 96 
defined. Next generation sequencing allows new approaches to identify rare mutations 97 
with large effect in CHD7. 98 
To this end, the NHLBI Pediatric Cardiac Genomics Consortium (PCGC) has 99 
collected more than 10,000 probands with CHD, including over 5,000 parent-offspring 100 
trios8. Previous exome sequencing of 1,228 parent-offspring trios from this cohort has 101 
shown that ~10% of cases are attributable to de novo mutations (DNMs) in an estimated 102 
> 400 target genes, including dramatic enrichment for damaging mutations in genes 103 
encoding chromatin modifiers9-11. Moreover, these studies have demonstrated a striking 104 
shared genetic etiology between CHD and neurodevelopmental disorders (NDD)6,10. 105 
Nonetheless, few new individual genes have been definitively implicated owing to the 106 
high locus heterogeneity, and transmitted variants have not to date been 107 
comprehensively studied. 108 
Genetic studies of humans and mice predict a role for transmitted variants with 109 
large effect12,13. Their discovery in humans has likely been limited by variations to the 110 
Mendelian paradigm such as high locus heterogeneity, markedly impaired reproductive 111 
fitness of individuals harboring risk genotypes, variable expressivity of mutant genotypes, 112 
and incomplete penetrance of mutant genotypes12. Detection of disease loci in this 113 
setting requires large cohorts of well-phenotyped subjects coupled with comprehensive 114 
genomic data and robust statistical methods. 115 
Here, we present the first comprehensive analysis of the combined impact of rare 116 
recessive and dominantly transmitted variants, and DNMs on CHD identified from 117 
analysis of whole exome sequencing (WES) of a single large CHD cohort. The results 118 
implicate new genes in CHD pathogenesis and expand the phenotypic spectrum 119 
associated with previously implicated genes. 120 
 121 
RESULTS 122 
 123 
Cohort Characteristics and Sequencing 124 
 125 
We studied 2,871 probands with CHD comprising 2,645 parent-offspring trios 126 
and 226 singletons (Supplementary Excel S1). These include 1,204 previously 127 
reported trios10 and 1,441 new trios. Patients were recruited to the PCGC and the 128 
Pediatric Heart Network (PHN) programs; cardiac and extracardiac phenotypic data on 129 
all probands were collected as previously described8 (Supplementary Table S1). The 130 
ethnicities and gender of probands are shown in Supplementary Table S2. We 131 
excluded patients with clinically ascertained trisomies and CHD-associated CNVs. The 132 
distribution of cardiac lesions, extra-cardiac manifestations, and syndromes clinically 133 
diagnosed prior to enrollment are documented in Supplementary Tables S3a-c. 134 
Genomic DNA from all trios and singletons underwent exome sequencing (see 135 
Methods). In parallel, sequence data from 1,789 control trios comprising unaffected 136 
siblings of autism probands and their parents was analyzed14. Cases and controls 137 
showed similar sequencing metrics with sufficient depth of coverage to make confident 138 
calls of DNMs and transmitted variants in the vast majority of targeted bases 139 
(Supplementary Table S4). Variants were called using Genome Analysis Toolkit (GATK) 140 
Haplotype Caller15,16 and annotated for allele frequencies in Exome Aggregation 141 
Consortium (ExAC)17, 1,000 Genomes18 and Exome Variant Server (EVS). DNMs were 142 
called as described in methods9,10. The likelihood of missense variants being deleterious 143 
was inferred using MetaSVM19. 144 
 145 
Recessive Genotypes Enriched in CHD 146 
 147 
We used genotype data to perform principal component analysis (PCA) and 148 
assess the inbreeding coefficient of all probands. CHD cases were more frequently of 149 
non-European ancestry and had a higher inbreeding coefficient compared to controls 150 
(Supplementary Figure S1). These differences affect expected recessive genotype 151 
(RG) frequencies, complicating direct comparison of cases and controls. Accordingly, we 152 
implemented a binomial test to quantify the enrichment of damaging RGs in a specific 153 
gene or gene set in cases, independent of controls. This method estimates the expected 154 
frequency of rare damaging variants in each gene from the de novo probability, then 155 
determines the probability of the observed RGs in each gene occurring by chance, 156 
adjusting for the effect of inbreeding (see Methods and Supplementary Figures S2-S6). 157 
We first tested whether genes previously implicated in CHD in humans or in 158 
human orthologs of genes implicated in recessive CHD in mouse harbored more 159 
damaging RGs than expected using the polynomial model. To this end, we prospectively 160 
curated a set of 212 human CHD genes (H-CHD genes) from the Online Mendelian 161 
Inheritance in Man (OMIM) and published data11, and human orthologs of 61 mouse 162 
CHD genes (M-CHD genes) identified in a forward recessive screen for structural CHD 163 
(Supplementary Excel S2)13. The human gene set comprised 104 genes causing 164 
dominant CHD, 85 recessive genes, 12 X-linked genes, and 11 genes with evidence for 165 
both dominant and recessive transmission. After accounting for 20 genes identified in 166 
both human and mouse studies, the combined set comprised 253 unique human genes 167 
(Supplementary Excel S2). 168 
We identified rare (allele frequency < 0.001) likely loss-of-function (LoF; 169 
frameshift, nonsense, canonical splice site, and start loss), likely damaging missense 170 
variants (by MetaSVM; D-Mis), and non-frameshift insertion/deletion variants, and 171 
identified homozygous or compound heterozygous genotypes comprising these alleles. 172 
This identified 467 putative damaging RGs in CHD cases (Supplementary Excel S3) 173 
and 165 in controls (Supplementary Excel S4). 174 
We then used the one-tailed binomial test to determine whether damaging RGs 175 
were enriched among 96 genes previously implicated in recessive CHD in humans 176 
(Table 1a). This gene set showed many more damaging RGs than expected (observed 177 
29 vs. expected 6.7, enrichment = 4.4, P = 8.0x10-11; Table 1a, Supplementary Figure 178 
S5b, Supplementary Table S5). In contrast, this gene set showed zero RGs in controls 179 
(Table 1b). After addition of the 41 recessive genes unique to mouse, there were 34 180 
damaging RGs in known recessive human or mouse genes compared to 11.1 expected 181 
(enrichment = 3.1, P = 1.4x10-8; Table 1a). 182 
We next added 116 genes previously implicated in monoallelic CHD. This 183 
showed an additional 17 damaging RGs in 9 genes (cumulative total, observed 51 vs. 184 
expected 25.2, enrichment = 2.0, P = 1.8x10-6; Table 1a). Similar results were obtained 185 
from constructing an expected distribution of RG without using polynomial fits by 186 
independently modeling homozygous and compound heterozygous genotypes (see 187 
Methods, Supplementary Table S6, and Supplementary Figures S7-S8). These 188 
findings are further corroborated using a burden test-based approach20,21 that also 189 
Table 1a. Damaging recessive genotypes in known CHD genes in 2,871 CHD cases
Gene set (# genes)
Observed Expected
Enrichment P-value# 
homozygotes
# compound
heterozygous
# unique 
genes
# recessive 
genotypes
# recessive 
genotypes
All genes (18,989) 265 202 391 467 - - -
Recessive Known Human (96) 19 10 16 29 6.65 4.36 8.0×10-11
Recessive Known Mouse or Human (137) 21 13 19 34 11.06 3.07 1.4×10-8
Known Mouse or Human CHD (253) 28 23 28 51 25.15 2.03 1.8×10-6
Table 1b. Damaging recessive genotypes in known CHD genes in 1,789 controls
Gene set (# genes)
Observed Expected
Enrichment P-value# 
homozygotes
# compound 
heterozygous
# unique 
genes
# recessive 
genotypes
# recessive 
genotypes
All genes (18,989) 22 131 146 165 - - -
Recessive Known Human (96) 0 0 0 0 2.61 0 1
Recessive Known Mouse or Human (137) 1 1 2 2 4.47 0.45 0.94
Known Mouse or Human CHD (253) 2 3 5 5 10.18 0.49 0.98
The expected number of recessivegenotypes was determined based on fitted values from the polynomial regression model using the damaging 
de novo probabilities. P-values were calculated using the one-tailed binomial probability. Values in bold are p-values exceeding the Bonferroni 
multiple testing cutoff = 0.05/(3×2) = 8.3×10-3
integrates proband phenotype information22 (see Methods and Supplementary Figure 190 
S9). These findings collectively provide strong evidence that that RGs in known CHD 191 
genes contribute to CHD in 0.9% of cases in this cohort. 192 
We examined the contribution of consanguinity to recessive genotypes in this 193 
cohort. 161 probands (5.6% of the total sequenced cohort) had homozygous segments 194 
spanning at least 0.35% of the genetic map, consistent with these probands being the 195 
offspring of the union of 3rd cousins or closer relationships (median 1.4% homozygosity 196 
for these probands, see Methods). We note that this group included 81 of 84 probands 197 
with a reported history of consanguinity, indicating that self-report was quite specific 198 
(96%) but not highly sensitive (50.3%) for consanguinity. 8.1% of these 161 199 
consanguineous probands had damaging RGs in known recessive human genes (13 200 
observed vs. 2.4 expected, 5.4-flold enrichment, P = 1.3x10-6; Supplementary Table 201 
S7). As expected, nearly all of these RGs (12) were homozygotes. In contrast, among 202 
the remaining 2710 probands, RGs were also highly significantly enriched (3.9-fold, 16 203 
observed vs. 4.1 expected, P = 5.3x10-6), however RG’s were found in only 0.6% of this 204 
group (Supplementary Table S7). Of the seven homozygotes in this group, five had 205 
inbreeding coefficients between 0.0015 and 0.0035, implying more distant parental 206 
relatedness, whereas two homozygotes and all nine compound heterozygotes in this 207 
group had inbreeding coefficients of zero. Thus, the probability that a RG contributes to 208 
CHD is strongly influenced by parental consanguinity. Similarly, 38% of RGs in known 209 
recessive CHD genes in our cohort were attributable to a GDF1 founder mutation (see 210 
below). Significant enrichment for RGs in known CHD genes persists after removal of 211 
recurrences of GDF1 homozygotes (Supplementary Table S8).  212 
To search for genes not previously associated with recessive CHD, we identified 213 
genes with > 1 damaging RGs.  We observed a total of 44 such genes compared to 26.4 214 
expected (enrichment = 1.7; P = 8.9x10-5 by permutation; see Methods); in contrast, 215 
there was no significant enrichment for genes with > 1 synonymous RG (observed = 167; 216 
expected = 156.7, P = 0.15 by permutation). This excess persisted after removal of 5 217 
genes (GDF1, ATIC, DNAH5, DAW1, LRP1) previously implicated in recessive CHD 218 
(enrichment = 1.6; P = 10-3 by permutation). GO ontology of this set revealed significant 219 
enrichment of terms involved in muscle cell development (GO:0055001, enrichment = 220 
29.5, FDR = 3.2x10-3). Genes in this GO term include KEL, MYH6, MYH11, NOTCH1, 221 
and RYR1 (Supplementary Excel S3 and S5). 222 
 223 
Founder Mutation in GDF1 in Ashkenazim 224 
 225 
We compared the observed number of damaging RGs in each gene to the 226 
expected distribution using the binomial test as described above. Quantile-quantile (Q-Q) 227 
plots showed that while the observed distribution of P-values closely followed the 228 
expected distribution for nearly all genes, two genes, GDF1 and MYH6, departed from 229 
the expected distribution and surpassed thresholds for genome-wide significance (P < 230 
2.6x10-6 = 0.05/18,989 tests) in cases (Figure 1a; Supplementary Table S9). Modeling 231 
of homozygous and compound heterozygous genotypes separately yielded similar 232 
results (Supplementary Table S10). In contrast, no genes approached genome-wide 233 
significance in controls (Figure 1b). 234 
GDF1 had 11 damaging RGs in apparently unrelated subjects compared with 235 
0.016 expected (enrichment = 692.6, one-tailed binomial P = 3.6x10-28; Supplementary 236 
Table S9). All 11 genotypes were confirmed by Sanger sequencing (Supplementary 237 
Figure S10). Ten of the eleven cases harbored the identical homozygous p.M364T 238 
variant, suggesting a founder mutation. The other GDF1 RG was p.364_364del/p.C227X. 239 
Consistent with a founder mutation, PCA showed that all ten p.M364T homozygotes 240 
clustered with Ashkenazim (Supplementary Figure S11), and the allele was absent 241 
among African, Asian, and Finnish European populations in ExAC. 242 
Multiple additional lines of evidence support this homozygous p.M364T genotype 243 
having a large effect on CHD risk among Ashkenazim. The p.M364T variant shows 244 
remarkable violation of Hardy Weinberg equilibrium among Ashkenazi CHD cases, with 245 
10 homozygotes and only 1 heterozygote among 204 Ashkenazi cases defined by PCA 246 
(P = 5.5x10-38, 1-df chi-square test with Yate’s correction; Supplementary Table S11a). 247 
In contrast, among 302 Ashkenazi autism parental controls and 926 additional 248 
Ashkenazi adults from an independent cohort without CHD, there were no homozygotes 249 
and only 12 heterozygotes (carrier frequency = 1.0%), providing strong evidence of 250 
association of homozygosity for p.M364T with CHD among Ashkenazim (two-sided 251 
Fisher’s Exact P = 2.8x10-9, Supplementary Table S11b). Lastly, all homozygotes 252 
shared the p.M364T variant on a common haplotype background, supporting identity by 253 
descent from a shared ancestor (Figure 2a). The extent of the shared haplotype varied 254 
widely in length (0.4-5.9 Mb; Figure 2a), indicating the absence of recent shared 255 
ancestry, and the minimum shared haplotype among all affected subjects was only 234 256 
kb. From this, the inferred coalescent time for the last shared ancestor is 50 generations 257 
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Figure 1. Quantile-quantile plots comparing observed versus expected P-values for recessive genotypes in 
each gene in cases and controls. Recessive genotypes (RGs) shown include LoF, D-Mis, and non frameshift 
insertion/deletions. The expected number of RGs in each gene was calculated from the total number of observed RGs 
as described in Methods. The significance of the difference between the observed and expected number of RGs was 
calculated using a one-sided binomial test. (a). Quantile-quantile (Q-Q) plot in cases. (b). Q-Q plot in controls. While 
the observed values closely conform to expected values in controls, two genes, GDF1 and MYH6, show a significantly 
increased burden of RGs in cases and survive the multiple-testing correction threshold. 
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Figure 2. Phenotypes and shared haplotypes 
among homozygotes for GDF1-p.M364T. (a). 
Extent of homozygous SNPs flanking homozygous 
GDF1-p.M364T genotypes. A 5.9 Mb segment of 
chromosome 19 extending across the location of 
the homozygous GDF1-p.M364T variant (denoted 
by red square) in each unrelated subject is 
depicted. At the bottom, tick marks indicate 
location of all SNPs found by exome sequencing 
among Ashkenazim in cases . Known SNPs are 
shown via their rs identifiers. Allele frequencies of 
novel SNPs are indicated by asterisks.  The 
closest heterozygous SNP to either side of the 
GDF1-p.M364T in each subject is shown as a 
white square; all SNPs between these two 
heterozygous SNPs, encompassed by the light 
blue bar, are homozygous for the same allele seen 
in other subjects, consistent with the p.M364T 
variant being identical by descent among all 
subjects. The length of each homozygous 
segment is indicated at the right of the panel. The 
maximum length of the homozygous segment 
shared by all subjects is 234 kb (shown as grey 
vertical bar), consistent with the mutation having 
been introduced into a shared ancestor many 
generations ago. (b). Cardiac and extracardiac
phenotypes of GDF1- p.M364T homozygotes. (c). 
Ribbon diagram of part of GDF1 homodimer
containing p.M364.  The hydrophobic helix from 
one subunit (yellow) sits above p.M364 on the 
other subunit (blue). (d). Space filling model of the 
segment of GDF1 containing the wild-type p.M364 
showing surface electrostatic charge 
(blue=positive, red=negative). (e).  Surface 
electrostatic charge of the segment containing 
mutant p.T364. Compared to wild-type, the mutant 
peptide shows a more negatively charged cavity.
Detailed phenotypes for patients carrying homozygousGDF1-M364T mutation
ID DORV TGA PS/PA Other cardiac phenotypes Extracardiac NDD
1-06122 + - + - -
1-00862 - L + VSD Inguinal hernia +
1-04480 - L + - +
1-06789 - - + TOF -
1-02374 - D + - NA
1-02531 + D + TAPVR -
1-02504 - - + TOF -
1-00532 - L - - +
1-00620 - D - - Inguinal hernia -
1-01815 - D + - NA
434kb
468kb
568kb
1,238kb
1,360kb
1,950kb
2,784kb
2,376kb
5,386kb
5,872kb
1-00620
1-02504
1-02531
1-02374
1-04480
1-06789
1-06122
1-01815
1-00532
1-00862
0.6 Mb
rs11574806 rs2239369* rs4613201rs2286923rs2287853 rs17679334* ** * * * * * ** ** *
HeterozygoteRare HomozygoteGDF1: p.M364T * Variants not in HaploView
Max Shared Haplotype Block (~234kb)
Chr19:18886588-19120591
as calculated by the DMLE+2.3 software23 (95% CI: 45 to 63 generations; 258 
Supplementary Figure S12). 259 
Also consistent with this genotype causing CHD and not merely being in linkage 260 
disequilibrium with another causal variant, the phenotype of the 10 p.M364T 261 
homozygotes is very similar to that previously described in patients with different 262 
recessive GDF1 mutations242424. Like prior cases, all GDF1 p.M364T homozygotes had 263 
D- or L-transposition of the great arteries and pulmonary stenosis/atresia (or both D/L-264 
TGA and PS/PA) (Figure 2b). GDF1 belongs to the transforming growth factor-beta 265 
(TGF-ß) superfamily. Previous studies of Gdf1 in mouse showed a critical role in left-266 
right asymmetry in embryonic development and in neural development25-27. GDF1 acts 267 
as a homodimer with two-fold inverted symmetry (Figure 2c and Supplementary 268 
Figure S13). The interaction surface between monomers comprises a hydrophophic D-269 
helix (residues 316-327) from one monomer and a shallow cavity formed by hydrophobic 270 
residues from the adjacent monomer; this interaction occurs reciprocally (i.e., twice per 271 
dimer). Met364 lies at the floor of the hydrophobic cavity (Figure 2d-e). The p.M364T 272 
substitution introduces the polar side chain of threonine into the hydrophobic cavity; in 273 
p.M364T homozygotes, we infer that both interaction surfaces between monomers are 274 
destabilized, impairing dimer formation and downstream signaling (Figure 2c). This 275 
mechanism is consistent with the observed recessive transmission. 276 
Collectively, these findings identify a recessive GDF1 founder mutation 277 
accounting for ~5% of severe CHD among Ashkenazim studied, including 18% of those 278 
with TGA (7 of 38), and 31% with TGA plus PS/PA (5 of 16). This finding has direct 279 
clinical implications for assessing risk of CHD among Ashkenazim. 280 
 281 
Recessive MYH6 Genotypes in Shone Complex 282 
MYH6 encodes the alpha cardiac heavy chain, a developmentally regulated 283 
protein that is most highly expressed in the embryonic heart. Dominant mutations in 284 
MYH6 have been shown to cause atrial septal defect28 and cardiomyopathy29,30. We 285 
identified seven rare damaging RGs in MYH6 compared with 0.482 expected 286 
(enrichment = 14.5, P = 7.6x10-7; Supplementary Table S9). These included diverse 287 
and very rare likely LoF alleles and D-Mis variants comprising five compound 288 
heterozygotes and two homozygotes, all validated by Sanger sequencing (Table 2, 289 
Supplementary Table S9, and Supplementary Figure S14). Five probands had left 290 
ventricular obstruction, including four meeting diagnostic criteria for Shone complex31, 291 
Table 2. Recessive MYH6 genotypes associatedwith Shone complex and valvular disease.
ID AA Change ExAC Ethnic Specific Freq
Shone 
complex
Detailed Cardiac 
Phenotype Cardiac Function Extracardiac NDD
Age at 
follow-up
1-00051 p.K1932X/p.A1891T 3.0×10
-5/
0 +
LSVC, abn MV, sub 
AS, valve AS, CoA
LV diastolic 
dysfunction
+ 
(LD) 22
1-01407 p.E98K 3.0×10-4 mitral atresia, DORV, CoA
mild RV systolic 
dysfunction Hypothyroid
+ 
(LD) 16
1-04847 p.R1899H/p.N598fs 0/0 +
parachute MV, BAV, 
CoA NL - 16
1-05009 p.A1327V/p.L388F 2.7×10
-3/
0 TA, PA
dilated, hyper-
trabeculated LV NA 0
1-06399 p.G585S/p.I512T 2.0×10
-4/
3.0×10-5 +
mitral stenosis, VSD, 
BAV, hypoplastic
transv. Ao
NL NA 0.08
1-06876 p.I1068T/c.3979-2A>C
1.5×10-5/
2.0×10-5 +
LSVC, abn mitral 
valve, valve AS, CoA dilated LV - 22
1-07343 p.R1610C 3.0×10-5 ASD/VSD NA NA NA
Abbreviations: ASD- Atrial septal defect, AS- Aortic stenosis, BAV- Bicuspid aortic valve, CoA- Coarctation of the aorta, DORV- Double
outlet right ventricle. MV- mitral valve, PA-Pulmonary atresia, TA-Tricuspid atresia, VSD-Ventricular septal defect. Extracardiac
manifestations refer to CHD probands displaying additional abnormalities not pertaining to the heart. NDD- neurodevelopmental disabilit ies
(+, -), LD-Learning Disability, NA – NDD status not attained as proband < age 1.
having mitral valve and aortic valve obstruction in addition to aortic arch obstruction 292 
(Table 2). These MYH6 genotypes accounted for 11% of the 37 patients with Shone 293 
complex in the sequenced cohort (enrichment = 57.45, two-sided Fisher’s exact 294 
P=6.7x10-5). 295 
 296 
Recessive Genotypes Enriched in Patients with Laterality Defects 297 
 298 
Among the major clinical CHD subgroups (laterality defects, left ventricular 299 
obstruction, conotruncal defects and others, outlined in Supplementary Table S3a), 300 
only laterality defects (heterotaxy and D-TGA) were enriched for damaging RGs in the 301 
known human and mouse CHD gene set. These included 21 damaging RGs in 13 genes 302 
compared to 4.8 expected RGs (enrichment = 4.4, P = 8.5x10-9; Supplementary Table 303 
S12). Significant enrichment was observed even after removing GDF1 RGs (enrichment 304 
= 3.2, P = 1.2x10-4). These genes included eight that have been previously implicated in 305 
laterality defects (ARMC4, BBS10, DAW1, DNAAF1, DNAH5, DYNC2H1, GDF1, and 306 
PKD1L1) and five that have not (ATIC, COL1A1, COL5A2, DGCR2, and MYH6). 307 
We performed GO ontology analysis of all 82 genes with LoF RGs observed in 308 
patients with any cardiac phenotype. This identified significant terms related to cilia 309 
structure and regulation, a predominant mechanism in laterality determination 310 
(Supplementary Excel S6). Genes in these GO terms included DNAI2, ARMC4, 311 
DNAH5, and DNAAF1 (proband phenotypes in Supplementary Excel S3). Although all 312 
four of these genes have been associated with human primary ciliary dyskinesia and 313 
situs inversus totalis, and Armc4 mutation leads to a range of CHD in mouse, only 314 
DNAH5 has been previously associated with human CHD32. 315 
 316 
Heterozygous LoF Mutations in FLT4 in Tetralogy of Fallot 317 
We next compared the frequency of rare (MAF ≤ 10-5) heterozygous LoF variants 318 
in 115 known dominant CHD genes in cases and controls to the number expected by 319 
chance using the binomial test (Supplementary Excel S7-S8). We found no significant 320 
enrichment in cases (enrichment = 1.1, P = 0.32; Supplementary Table S13a) or 321 
controls (enrichment = 0.7, P = 1; Supplementary Table S13b). Analysis of 322 
heterozygous LoF variants in all 212 known human CHD genes also showed no 323 
enrichment. 324 
To search for novel haploinsufficient CHD genes, we compared the observed 325 
distribution of rare heterozygous LoFs in each gene to the values expected by chance 326 
across the genome (see Methods). Q-Q plots (Supplementary Figure S15) showed 327 
that the observed distribution closely conformed to the expected in cases and controls 328 
with the exception of one gene, FLT4, which harbored eight different rare transmitted 329 
LoFs in cases, (enrichment = 15.5, P = 7.6x10-8, Supplementary Table S14). In addition, 330 
there were two de novo FLT4 LoF mutations, yielding a combined p-value of 9.8x10-10 331 
(p-values combined by the Fisher’s method, Figure 3). All FLT4 LoF variants were 332 
confirmed by Sanger sequencing (Supplementary Figure S16). 333 
FLT4 was highly intolerant to LoF mutation in the ExAC database (pLI = 1) and 334 
only one LoF allele in FLT4 was identified among 3,578 parental controls. There was no 335 
significant variation in coverage of coding bases across FLT4 exons between cases and 336 
controls. Examination of the pedigrees of the ten cases with FLT4 LoFs revealed four 337 
other affected family members with CHD and the FLT4 LoF mutation found in the 338 
proband (Figure 3a). Interestingly, however, FLT4 mutations showed incomplete 339 
penetrance, as only 4 of the 10 mutation-carrier relatives had CHD by report (estimated 340 
40% penetrance). 341 
FLT4 is a VEGF receptor known to be expressed in lymphatics and the 342 
vasculature and missense mutations affecting the kinase domain have been associated 343 
with hereditary lymphedema (Fig. 3b)33. Strongly supporting a pathogenic role for these 344 
FLT4 mutations, the phenotype of mutation carriers was highly homogeneous, with 9 of 345 
10 probands and 3 of their 4 affected relatives having a diagnosis of tetralogy of Fallot 346 
(TOF) (Figure 3). Among the 426 probands with TOF in our cohort, FLT4 mutations 347 
were found in 2.3% of TOF cases and were enriched 95.2-fold among TOF probands; 348 
this enrichment was highly unlikely to occur by chance (P = 1.9x10-12; Supplementary 349 
Table S15). 350 
 351 
De Novo Damaging Mutations Enriched in CHD Cases 352 
 353 
DNMs were identified in 2,645 parent-offspring case trios and 1,789 control trios, 354 
totaling 2,990 DNMs in cases (Supplementary Excel S9) and 1,830 in controls 355 
(Supplementary Excel S10). All had strong statistical support and were verified by in 356 
silico visualization of aligned reads. The observed number closely fit the expected 357 
Poisson distribution in cases and controls (Supplementary Figure S17). While CHD 358 
cases showed no enrichment for de novo synonymous or MetaSVM-tolerated (T-Mis) 359 
mutations, there was highly significant enrichment of de novo damaging (LoF and D-Mis) 360 
mutations (enrichment = 1.4, P = 2.4x10-17, Supplementary Table S16). From the 361 
Figure 3. FLT4 loss-of-function mutations in Tetralogy of Fallot (a). Pedigrees of 10 CHD kindreds with rare FLT4 loss-of-function (LoF) 
mutations are shown.  Subjects with and without CHD are shown as filled and unfilled symbols, respectively. Each kindred ID number is shown 
along with the FLT4 genotype of each subject and CHD phenotype of affected subjects. (b) Diagram of FLT4 protein is shown with seven 
immunoglobulin domains (Ig) and a kinase domain. The top panel shows LoF mutations associated with Tetralogy-type CHD, whereas the bottom 
panel displays missense mutations associated with the Milroy disease (Hereditary Lymphedema). 
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difference in the fraction of patients with damaging DNMs compared to expectation, we 362 
inferred that DNMs contribute to CHD in ~8.3% of cases. 363 
Expansion of the CHD cohort from previous analyses identified 66 genes with 364 
two or more damaging (LoF and D-Mis) DNMs (Figure 4a, Supplementary Table S17-365 
S18), including eight genes not previously implicated in CHD: AKAP12, ANK3, CTNNB1, 366 
FRYL, KDM5B, NAA15, POGZ, and PRRC2B. Further, CHD cases were markedly 367 
enriched for damaging mutations in 104 known dominant human CHD genes 368 
(enrichment = 9.3, P = 5.5x10-65; Supplementary Table S19). Similar findings were 369 
observed using an orthogonal method of disease gene discovery (see Methods and 370 
Supplementary Figure S18). 371 
We previously implicated DNMs in chromatin modifiers in CHD9,10. We now find 372 
89 damaging DNMs in 46 chromatin modifiers (including 58 LoFs; Figure 4b and 373 
Supplementary Table S20), (enrichment = 3.1, P = 8.7x10-20; Supplementary Table 374 
S21). Seventeen of these genes have not previously been found mutated. Collectively, 375 
damaging DNMs in chromatin modifiers are inferred to contribute to 2.3% of cases 376 
(Supplementary Table S21). Gene Ontology enrichment analysis using all genes 377 
harboring at least one de novo LoF mutation genes expressed in the top quartile of the 378 
14.5 mouse heart (HHE) gene set + LoF-intolerant gene set implicated the covalent 379 
chromatin modification gene set (GO:0016569; enrichment = 9.37, FDR q = 5.8x10-9) 380 
and other terms including histone modification (Supplementary Excel S11). 381 
 382 
De Novo Mutations Enriched in Isolated CHD 383 
 384 
We evaluated the contribution of DNMs to patients with isolated CHD, CHD with 385 
extracardiac malformation, CHD with NDD, and CHD with both EA and NDD, focusing 386 
on HHE gene set9 (Supplementary Table S22a). Unlike prior studies9,10, we found a 387 
significant enrichment of damaging DNMs in isolated CHD cases (defined as CHD 388 
without any extracardiac congenital anomalies, clinically diagnosed syndrome or 389 
neurodevelopmental abnormality, and limited to patients over age 1 for whom NDD 390 
questionnaires were completed at entry into the study), contributing to ~3.1% of cases 391 
(1.5-fold enrichment, P = 8.5x10-4; Supplementary Table S22a). We further estimated 392 
that damaging DNMs in the known CHD genes can account for ~50% (13/26) of the 393 
excess burden of mutations in isolated CHD. By comparison, DNMs contributed to 6% - 394 
8% of probands with extracardiac features (either CHD + EA alone or CHD + NDD 395 
alone), and to a very high fraction of cases with CHD + EA + NDD, 28% of cases (95% 396 
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Figure 4. Genes with multiple damaging 
de novo mutations and in chromatin 
modification genes are enriched for high 
expression in developing heart and 
intolerance to loss-of-function mutation. 
(a) 66 genes with 2 or more damaging de 
novo mutations are plotted for percentile 
rank of heart expression in developing 
mouse heart at E14.5 (x axis, 0-100) and 
intolerance to loss-of-function (LoF) mutation 
(pLI) in the ExAC database (y axis, 0-1.0).  
Multihit genes are highly enriched (N=31) for 
genes that are highly expressed in 
developing heart and intolerant to loss-of-
function mutation (pLI ≥ 0.99). (b) 
Enrichment of damaging mutations in 
chromatin modifiers in genes highly 
expressed in developing heart and intolerant 
to loss-of-function mutation. 
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CI: 19.6%-36.7%, 5-fold enrichment, P = 1.6x10-29; Supplementary Tables S22a-d and 397 
S23). 398 
De novo mutations are Enriched in Autism-Associated Genes. 399 
We previously showed unexpected overlap of genes harboring damaging DNMs 400 
between CHD and neurodevelopmental disorders9,10. With exome sequencing completed 401 
for two large cohorts of well-phenotyped autism patients comprising 4,778 parent-402 
offspring trios34,35, we compared the genes harboring damaging DNMs in our CHD 403 
cohort and these autism cohort trios34,35. There was highly significant overlap of these 404 
genes (Supplementary Table 24a), driven by genes with high expression in both 405 
developing heart and brain. This included 19 genes with LoF mutations in both cohorts 406 
(enrichment 5.2, P < 10-6) and 48 genes with damaging mutations in both (enrichment 407 
2.8, P < 10-6; Supplementary Table 24b). Notably, 67% (21/31) of CHD patients with 408 
available neurodevelopmental data harboring LoF DNMs in the overlapping gene set 409 
had NDD, compared to 32.8% in the total cohort with certain NDD status; OR = 4.3; two-410 
sided Fisher’s P = 1.4 x10-4; Supplementary Table S25). Three of the CHD cases with 411 
mutations in the overlapping gene set had an autism diagnosis at entry into the study. 412 
Notably, 14/35 genes with LoF DNMs in both the CHD and autism cohorts are chromatin 413 
modifiers (enrichment =14.7, P < 10-6 by permutation; Supplementary Table S25). Most 414 
strikingly, 87% of all patients who were evaluated for NDD and have LoF DNMs in 415 
chromatin modifiers had an NDD diagnosis at study entry. 416 
 417 
Meta-Analysis of Damaging De Novo and Loss-of-function Heterozygous Variants 418 
 419 
We tested each gene for an excess of de novo and transmitted heterozygous 420 
variants using Fisher’s method to combine the P-values from damaging de novo and 421 
LoF heterozygous LoF variants (degrees of freedom = 4). Seven genes passed genome 422 
wide significance (P < 2.6x10-6 [0.05/18,989 genes]; Table 3). These included genes that 423 
were largely driven by damaging DNMs (CHD7, KMT2D, PTPN11, and RBFOX2) and 424 
three genes that predominantly had transmitted LoF mutations (FLT4, SMAD6, and 425 
NOTCH1) (Table 3). Of note, 12 of the top 25 (48%) genes are known CHD genes 426 
including CHD7, KMT2D, PTPN11, NOTCH1, SMAD6, GATA6, ELN, PTEN, RPL5, 427 
NSD1, NODAL, and SOS1. Those among the top 25 genes that have not previously 428 
been linked to CHD risk but are HHE and LoF-intolerant include SMAD2 (a transducer of 429 
TGF-beta signaling), and FRYL (a transcriptional activator). 430 
Meta-analysis was performed by combining the p-values from damaging de novo mutations and loss-of-function (LoF) heterozygous
mutations using the Fisher's method with 4 degrees of freedom. The top 25 genes are shown. Genes which are bolded surpass the
Bonferroni mult iple testing correction (2.6×10-6, 0.05/18,989) for p-values tabulated by either de novo, heterozygous, or meta-
analysis. H-CHD: Known human CHD genes. M-CHD: Known mouse CHD genes. Chromatin: Chromatin modification genes consists
of 546 genes in GO:0016569.* denotes that at least one of the carriers has unknown transmission.
Table 3. Top 25 genes in the meta-analysis of damaging de novomutations and loss-of-function heterozygous mutations in probands
Gene
Damaging de novo LoF heterozygotes
Meta P-value pLI HHE Rank Gene Set# Damaging P-value # LoF P-value
CHD7 14 1.6×10-20 0 1 7.5×10-19 1 93.4 H-CHD/Chromatin
KMT2D 16 2.1×10-20 1* 0.86 8.5×10-19 1 96.8 H-CHD/Chromatin
PTPN11 9 4.6×10-17 0 1 1.8×10-15 1 94.2 H-CHD
FLT4 2 5.2×10-4 8 7.6×10-8 9.8×10-10 1 74.4 NA
NOTCH1 5 2.7×10-5 6* 1.8×10-4 9.4×10-8 1 87.9 H-CHD
RBFOX2 3 3.4×10-7 1* 0.18 1.1×10-6 0.99 97.8 NA
SMAD6 1 0.012 8 6.0×10-6 1.3×10-6 0 78.3 M-CHD
GATA6 4 2.4×10-7 0 1 3.8×10-6 N/A 94.8 H-CHD
ELN 2 1.3×10-4 5* 8.7×10-3 1.7×10-5 0 79.8 H-CHD
CCDC154 0 1 7* 5.5×10-6 7.2×10-5 0.31 18.4 NA
SLCO1B3 0 1 9 6.6×10-6 8.5×10-5 0 11.7 NA
GPBAR1 2 2.6×10-5 1 0.27 9.1×10-5 0 19.9 NA
PTEN 2 6.0×10-5 1 0.16 1.2×10-4 0.98 77.9 H-CHD
RPL5 2 6.2×10-5 1 0.16 1.3×10-4 0.99 97.9 H-CHD
NSD1 5 1.0×10-5 0 1 1.3×10-4 1 94.8 H-CHD/Chromatin
SAMD11 2 1.8×10-4 4* 0.06 1.4×10-4 0 N/A NA
C21ORF2 0 1 5 1.2×10-5 1.5×10-4 0.01 46.7 NA
NODAL 0 1 4 1.2×10-5 1.5×10-4 0.95 16.4 H-CHD
SMAD2 3 5.5×10-5 1 0.24 1.6×10-4 0.99 74.7 NA
H1FOO 0 1 4 1.6×10-5 1.9×10-4 0.4 10.3 NA
FRYL 2 2.8×10-3 5* 8.3×10-3 2.8×10-4 1 84.4 NA
KDM5B 3 2.9×10-5 2* 0.86 2.9×10-4 0 86 Chromatin
POGZ 3 2.5×10-5 0 1 2.9×10-4 1 83.8 Chromatin
SOS1 3 2.6×10-5 0 1 3.0×10-4 1 67.9 H-CHD
TBX18 1 0.02 3 1.8×10-3 3.0×10-4 1 72.6 NA
SMAD6, an inhibitor of BMP signaling, had 8 transmitted and one de novo LoF 431 
(Meta P = 1.3x10-6; Table 3). Patients with SMAD6 mutations had TOF, hypoplastic left 432 
heart syndrome, coarctation and D-TGA. Zero LoF variants were noted in 7,156 control 433 
alleles (OR = Inf, one-sided Fisher’s Exact P = 6.8x10-4). Case-control analysis 434 
comparing 2,063 CHD European cases (7 mutation carriers) with 30,216 ExAC non-435 
Finnish European controls (5 carriers) also showed marked enrichment (OR = 20.5, two-436 
sided Fisher’s P = 2.7x10-6). One parent with a transmitted LOF SMAD6 allele had a 437 
BAV, and the remainder did not have a history of CHD, and while parents did not have 438 
cardiac imaging, unrecognized severe CHD would be unlikely. Monoallelic SMAD6 439 
missense variants have been previously identified in three sporadic cases of bicuspid 440 
aortic valve and mitral valve disease36, though the statistical relevance of these 441 
mutations to CHD was not established. Interestingly, LoF mutations in SMAD6 with 442 
incomplete penetrance have also been implicated in midline craniosynostosis, with a 443 
common variant near BMP2 modifying penetrance37. Our findings suggest that the 444 
phenotype resulting from SMAD6 mutation is highly variable, dependent on additional 445 
genetic or environmental factors. 446 
 447 
DISCUSSION 448 
 449 
This study represents the largest genetic investigation of CHD, and the first 450 
analysis of the combined contribution of transmitted and de novo variants to CHD. By 451 
more than doubling the size of the studied cohort, many additional genes have been 452 
implicated. Our search for disease-associated transmitted variants and pathways was 453 
markedly enhanced by implementation of a gene burden analysis that estimates the 454 
expected number of recessive or dominant genotypes independent of control subjects 455 
and which accommodates variation in inbreeding and ethnic background. While the 456 
explicit extension of the expected frequency of DNMs to standing variation can be 457 
confounded by the impact of selection and drift on allele frequencies over subsequent 458 
generations, our analysis demonstrates that this approach is robust for estimating the 459 
expected frequency of rare transmitted variants, which are more likely to be newly 460 
introduced into the population. This approach will have application to many studies 461 
searching for the contribution of transmitted rare variants to human traits in the absence 462 
of family linkage data. 463 
Rare transmitted genotypes accounted for at least 1.8% of CHD in this cohort. 464 
This number is an underestimate because it only takes into account the impact of rare 465 
mutations in known CHD genes plus additional genes that have reached genome-wide 466 
significance. Moreover, these genotypes are likely underrepresented in the general 467 
population owing to purifying selection, so the expected number is likely lower than the 468 
calculated frequency. Included in this group was a founder mutation in GDF1 that 469 
accounted for 5% of all severe CHD in the Ashkenazi population studied, and an even 470 
higher percentage of Ashkenazi cases with TGA (18%), particularly those who also have 471 
PS/PA (31%). Genotyping for this specific variant, which has an allele frequency of 472 
~0.6% in Ashkenazim, can immediately be used for diagnosis and population-based risk 473 
assessment. 474 
It is interesting to note that enrichment of damaging RGs was most significant in 475 
patients with laterality defects. The epidemiology of laterality defects suggests a 476 
contribution by RGs: they have the highest recurrence risk within families of any CHD12 , 477 
are more prevalent in populations with high consanguinity38, and conversely have no 478 
enrichment of damaging DNMs9,10. 479 
We also found new recessive phenotypes arising from genes previously 480 
implicated in CHD caused by monoallelic mutations, including RGs in MYH6 in 11% of 481 
Shone complex cases. Shone complex features multiple levels of left-ventricular outflow 482 
obstruction, posing a challenge for surgical management39, and no clear genetic cause 483 
has yet been identified. MYH6 compound heterozygous mutations have been identified 484 
in two patients with another left-ventricular obstructive lesion, hypoplastic left heart 485 
syndrome (HLHS) associated with reduced ventricular ejection fraction40. Further, a link 486 
was identified between monoalleleic variants in MYH6 and decreased transplant-free 487 
survival in patients with HLHS41. This suggests that patients with Shone complex due to 488 
biallelic MYH6 mutation may be at particular risk of developing ventricular dysfunction 489 
and their early identification may allow intervention leading to improved outcome. Other 490 
genes without previously described recessive phenotypes included CHD7, COL1A1, 491 
COL5A2, FBN2, NOTCH1, NSD1, and TSC2, as well as DGCR2, and DAW1, LRP1, 492 
and MYH10, which previously had been implicated only in mouse CHD. 493 
Analysis of rare dominant variants strongly implicated LoF variants distributed 494 
throughout the type 3 VEGF receptor FLT4 and showed that they predominantly result in 495 
TOF. Among 10 probands with FLT4 LoFs, none had NDD and only 1 had EA, unlike 496 
25% of all TOF probands in this study who have NDD and/or EA. FLT4 LoF mutations 497 
are distinct from reported heterozygous missense mutations in the FLT4 kinase domain 498 
that impair kinase activity and result in defective lymphatic development42. It is, thus, 499 
clear that loss of FLT4 kinase function is not equivalent to a null allele. FLT4 functions 500 
that are kinase-independent may be preserved in the kinase-mutant alleles but lost in 501 
null alleles. Further studies of the expression and role of FLT4 in the developing heart 502 
will be of interest. 503 
Doubling the size of our sequenced cohort more than doubled the identified CHD 504 
risk genes. The current data set includes 66 genes with two or more damaging DNMs 505 
compared to 21 previously, and 19 with two or more LoF DNMs compared to five 506 
previously10. Among the most highly enriched gene sets in which 72%-85% of genes are 507 
expected to confer risk (i.e. 17 HHE genes with two or more LoF DNMs; 31 HHE + 508 
intolerant genes with two or more damaging mutations; 11 chromatin modifiers with two 509 
or more damaging DNMs), we identify 19 unique genes (AKAP12, ANK3, CAD, CLUH, 510 
CTNNB1, FRYL, GANAB, KDM5A, KDM5B, KMT2C, MINK1, MYRF, NAA15, POGZ, 511 
PRRC2B, RBFOX2, RYR3, U2SURP, and WHSC1) that have not been implicated in 512 
CHD prior to our studies of this CHD cohort. DNMs are highly enriched in cases with 513 
neurodevelopmental abnormalities and extra-cardiac structural manifestations, 514 
contributing to more than a quarter of these cases. Importantly, we report for the first 515 
time a significant contribution of DNMs to isolated CHD, occurring in 3.1% of cases. 516 
From the distribution of genes with multiple damaging DNMs, the estimate of the number 517 
of genes in which DNMs contribute to CHD in this cohort is 443 (95% CI = [154.1, 731.9]; 518 
Supplementary Figure S19; see Methods). 519 
Pathway analysis identified distinct biological mechanisms underlying de novo 520 
and inherited CHD. As previously reported, chromatin modifiers represent the top terms 521 
associated with DNMs contributing to CHD. Eleven chromatin modifiers have two or 522 
more damaging DNMs, and we estimate from a maximum likelihood approach (see 523 
Methods) that ~38 genes in this pathway contribute to CHD (Supplementary Figure 524 
S20). The implication of LoF DNMs in writers, erasers and readers of many different 525 
specific chromatin marks underscores the importance of dosage sensitivity of these 526 
genes. Together these findings suggest that heart development depends on precise 527 
control of transcription mediated by changes in chromatin state in response to 528 
developmental signals43-45. After removing chromatin modifiers from GO term enrichment 529 
analysis, several terms broadly involved in developmental processes show enrichment 530 
(Supplementary Excel S12). Extension of pathway analysis to genes with damaging 531 
RGs demonstrated enrichment of genes involved in cilia formation and function. These 532 
genes have long been known to play a critical role in establishment of the left-right body 533 
axis in early development, and mutations in this pathway play a frequent role in 534 
development of heterotaxy. Understanding the mechanisms underlying the effects of 535 
these biological pathways will be of great interest in determining mechanisms of normal 536 
and abnormal human development. 537 
It will become important to link the genetic causes of CHD to patient outcomes. 538 
We report striking overlap of genes mutated in CHD and autism. Genes mutated in both 539 
are enriched > 2.7-fold among genes that are highly expressed in both developing heart 540 
and brain. In particular, patients in our cohort with LoF mutations in chromatin modifiers 541 
are at very high risk of NDD (87%). In contrast, none of our patients with FLT4 mutation 542 
and TOF had NDD, which underscores the impact of specific mutations on risk of CHD 543 
patients having NDD/autism. These observations identify a set of CHD genes that may 544 
permit presymptomatic identification of patients with CHD who are at high risk for autism, 545 
and would be good candidates for early neurodevelopmental intervention46. Conversely, 546 
virtually all patients with LoF mutations in chromatin modifiers who have been 547 
ascertained for autism studies do not have CHD35, indicative of variable expressivity of 548 
CHD, and raising the possibility that NDD phenotypes may also have variable 549 
expressivity. 550 
Despite these advances, the pathogenesis of a large fraction of CHD cases 551 
remains unknown. Potential explanations include contributions from more common 552 
variants, structural variants that have eluded detection by WES, variants in the non-553 
coding regions, polygenic inheritance and possible gene-environment 554 
interactions6,37,47,48 . Monte Carlo simulations suggest that two or more damaging DNMs 555 
have been identified in ~10.5% of risk loci, and that sequencing 10,000 trios will yield 556 
170.1 risk genes, predicting 38% saturation of all CHD risk genes acting by DNMs 557 
(Supplementary Figure S21). It is clear that loci suggested from human studies can be 558 
further substantiated at low cost by orthogonal approaches engineering mutations into 559 
model organisms and cells49. This study indicates that continued sequencing of large, 560 
well-phenotyped cohorts will provide an increasingly complete picture of the genetic 561 
underpinnings of CHD, allowing new insight into mechanisms governing human 562 
development, improved prediction of clinical outcome, and the opportunity to mitigate 563 
these risks. 564 
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